



ONLINE SUPPLEMENTARY DATA

Supplementary Figure 1. Study flow chart: Patient disposition for apremilast, methotrexate, and bDMARD initiators with oligoarticular psoriatic arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. bDMARD: biologic disease-modifying anti-rheumatic drug.



Supplementary Figure 2. Achievement of HAQ-DI MCID: Proportion of patients with HAQ-DI score available at baseline achieving ≥ 0.35 -point improvement in the Health Assessment Questionnaire-Disability Index minimum clinically important differences at 6 months. bDMARD: biologic disease-modifying anti-rheumatic drug. n/N: number of responders/number of patients with sufficient data for evaluation.



Supplementary Figure 3. Nail disease complete responders: Proportion of patients with presence of physician-reported clinical characteristics of nail psoriasis at baseline who were without physician-reported clinical characteristics of nail psoriasis at 6 months. bDMARD: biologic disease-modifying anti-rheumatic drug. n/N=number of responders/number of patients with sufficient data for evaluation.

